ArticleHuman genetics2026
Multiscore, a gene ranker powered by artificial intelligence and real-world clinical data, shows high sensitivity for the molecular diagnosis of Mendelian disorders in nearly 10,000 exomes and genomes.
Article in Human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine Learning, Large Language Models, and Multimodal AI for Diagnosing Pediatric Rare Diseases: Scoping Review.Journal of medical Internet research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A challenge for clinical exome and genome sequencing (ES/GS) analysis is correlating the clinical presentation of the cases being tested with known gene-phenotype associations (GPAs). We developed Multiscore, a gene prioritization tool, to facilitate gene-level predictions of phenotypic fit. Multiscore combines data inputs and algorithms to generate similarity subscores that feed a random forest (RF) classifier trained to predict the probability of association between the patient’s clinical features and the gene. The reference GPAs are extracted from: (1) OMIM, (2) patient descriptions in the literature, and (3) GeneDx (GDx) clinical data. We used 9,989 ES/GS cases to assess performance of the tool in combination with genotype filtering. Genotype filters rendered an average of 173 genes with variants requiring clinical review. Multiscore prioritized the reported positive gene with a median rank of 3 and mean rank of 6.35. The average recall (sensitivity) of Multiscore was 33% in the top 1, 69% in the top 5, 83% in the top 10, and 93% in the top 20 ranked genes. Multiscore was able to handle non-exact HPO term matches allowing the use of real-world clinical data. 74 genes lacking OMIM entries were prioritized using only the GDx and literature datasets. Multiscore allows the phenotype review to prioritize the most relevant genes, increasing case throughput and broadening access to diagnoses for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.